Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: J Nucl Med. 2013 Dec 12;55(1):23–29. doi: 10.2967/jnumed.113.122630

FIGURE 5.

FIGURE 5

Inter- and intra-patient heterogeneity of 64Cu-DOTA-trastuzumab tumor uptake. Short horizontal lines indicate intra-patient mean SUVmax. Data are from Day 1 (n=49), or Day 2 (n = 7) for lesions not included in the Day 1 scan. Six of the Day 2 lesions are for Patient 8, for whom data from 2 of the 3 scanned bed positions on Day 1 were lost due to scanner malfunction. The other Day 2 lesion is for Patient 6. Patients 6 and 7 received trastuzumab doses of 5 mg; the others received 50 mg.